Quadrant Capital Group LLC Trims Position in Hologic, Inc. (NASDAQ:HOLX)

Quadrant Capital Group LLC lessened its holdings in shares of Hologic, Inc. (NASDAQ:HOLXGet Rating) by 18.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 788 shares of the medical equipment provider’s stock after selling 181 shares during the quarter. Quadrant Capital Group LLC’s holdings in Hologic were worth $60,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. TD Asset Management Inc. increased its holdings in shares of Hologic by 3.7% during the 3rd quarter. TD Asset Management Inc. now owns 1,484,955 shares of the medical equipment provider’s stock worth $109,605,000 after buying an additional 53,021 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of Hologic by 93.3% during the 3rd quarter. Jennison Associates LLC now owns 676,089 shares of the medical equipment provider’s stock worth $49,902,000 after buying an additional 326,308 shares during the last quarter. Pinebridge Investments L.P. increased its holdings in shares of Hologic by 19.5% during the 3rd quarter. Pinebridge Investments L.P. now owns 289,794 shares of the medical equipment provider’s stock worth $21,390,000 after buying an additional 47,360 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG increased its holdings in shares of Hologic by 10.3% during the 3rd quarter. B. Metzler seel. Sohn & Co. Holding AG now owns 22,470 shares of the medical equipment provider’s stock worth $1,659,000 after buying an additional 2,097 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of Hologic by 2.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,039,635 shares of the medical equipment provider’s stock worth $150,546,000 after buying an additional 50,826 shares during the last quarter. Institutional investors and hedge funds own 93.12% of the company’s stock.

NASDAQ:HOLX opened at $79.99 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.74 and a quick ratio of 2.34. The firm has a 50-day moving average of $73.23 and a two-hundred day moving average of $73.02. The stock has a market cap of $20.00 billion, a P/E ratio of 12.03, a PEG ratio of 1.23 and a beta of 1.12. Hologic, Inc. has a 1-year low of $60.10 and a 1-year high of $81.04.

Hologic (NASDAQ:HOLXGet Rating) last posted its quarterly earnings data on Wednesday, February 2nd. The medical equipment provider reported $2.17 earnings per share for the quarter, beating analysts’ consensus estimates of $1.20 by $0.97. Hologic had a net margin of 31.23% and a return on equity of 48.46%. The company had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.21 billion. During the same period in the prior year, the company posted $2.86 EPS. The firm’s revenue for the quarter was down 8.6% on a year-over-year basis. As a group, equities analysts expect that Hologic, Inc. will post 5.09 earnings per share for the current year.

In other Hologic news, insider Sean S. Daugherty sold 2,179 shares of the firm’s stock in a transaction dated Thursday, February 24th. The shares were sold at an average price of $71.14, for a total value of $155,014.06. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 1.54% of the company’s stock.

A number of analysts have recently commented on HOLX shares. StockNews.com started coverage on Hologic in a report on Thursday, March 31st. They set a “buy” rating for the company. Raymond James lowered their price target on Hologic from $88.00 to $84.00 and set an “outperform” rating for the company in a report on Thursday, February 3rd. Wells Fargo & Company lowered their price target on Hologic from $95.00 to $90.00 and set an “overweight” rating for the company in a report on Thursday, February 3rd. Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and lowered their price target for the company from $85.00 to $78.00 in a report on Wednesday, December 15th. Finally, Morgan Stanley lowered their price target on Hologic from $76.00 to $75.00 and set an “equal weight” rating for the company in a report on Thursday, February 3rd. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $81.78.

Hologic Profile (Get Rating)

Hologic, Inc engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery.

Recommended Stories

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.